论文信息 - Radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): Results from a randomized, placebo-controlled, phase II study - 字舞流文

Radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): Results from a randomized, placebo-controlled, phase II study

C. Parker | S. Nilsson | Ø. Bruland | B. Lennernäs | D. Johannessen | L. Franzén | M. Sokal | J. Tennvall | R. Blom | C. Tyrrell